Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 2Meningeal Carcinomatosis 2Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Medulloblastoma 1Desmoplastic Small Round Cell Tumor 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 4Irinotecan 4eribulin 2Topotecan 2LY2940680 2technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1surufatinib 1sonidegib 1soblidotin 1ribociclib 1regorafenib 1pegfilgrastim 1palbociclib 1omburtamab I-131 1lenvatinib 1iso-sulfan blue 1dostarlimab 1dinutuximab 1copanlisib 1cixutumumab 1ceritinib 1bempegaldesleukin 1amino-acid, glucose, and electrolyte solution 1abemaciclib 1Vincristine 1Pemetrexed 1Nivolumab 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Rhabdomyosarcoma × omburtamab I-131 × Clear all
NCT00089245 2023-12-26

Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Y-mAbs Therapeutics

Phase 1 Terminated
177 enrolled
CNSSarcoma

Brain Neoplasms, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Meningeal Carcinomatosis, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡